NCT01852409Unknown1 期
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.
Peking University2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- adverse events
研究概览
简要总结
Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab for the palliation of malignant ascites might be a novel choice for refractory malignant ascites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form;
- •Histologically or cytologically confirmed non-squamous cell carcinoma，including colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, bile duct cancer, ovarian cancer, peritoneal primary tumor;Ascites were diagnosed by ultrasound or CT and confirmed malignant ascites by cytology;
- •failed to standard systemic therapy and / or no appropriate treatment for the treatment for malignant ascites
- •Age 18-70 years;
- •Performance Status- Eastern Cooperative Oncology Group (ECOG)≤2;
- •Life expectancy of at least 8 weeks;
排除标准
- •systematic anti-cancer therapy, including chemotherapy (intraperitoneal chemotherapy), radiation therapy, immunotherapy, biological or hormone therapy performed within 2 weeks;
- •tyrosine kinase inhibitors or monoclonal antibodies of anti-vascular endothelial growth factor (VEGF) performed within 4 weeks;
- •Laboratory tests:Absolute neutrophil count<1.0x109/L,Platelet count<75x 109/L,Hemoglobin<8g/dl,PT-INR≥1.5 times upper limit of normal (ULN);Bilirubin≥2 x ULN,AST and ALT≥2.5 times ULN(no liver metastasis),≥5 times ULN(with liver metastasis)Creatinine≥1.5 times ULN or calculated creatinine clearance, using the Cockcroft-Gault formula,<40 mL/min;
- •uncontrolled hypertension:systolic pressure ≥160 mmHg,or diastolic pressure≥100mmHg
- •Known history of severe heart disease,uncontrolled or symptomatic angina, congestive heart failure,clinically significant arrhythmias,myocardial infarction within six months;
- •active (severe or uncontrolled) bleeding (hemorrhage within 3 months> 30 ml), hemoptysis (fresh blood, 4 weeks> 5 ml), bloody ascites
- •thrombosis, tumor thrombus events (including arterial/venous thrombosis, tumor thrombosis, pulmonary embolism, transient ischemic attack)within 12 months;
- •Portal hypertensive disease or severe liver disease, including various types of cirrhosis, obstructive jaundice;
- •concurrent gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative colitis and other gastrointestinal diseases according to investigators' determination that may cause gastrointestinal bleeding or perforation;
- •concurrent severe respiratory disease, or chronic therapy with oxygen or corticosteroids, such as chronic obstructive pulmonary disease, interstitial lung disease, etc.
- •Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2 or not recovered from surgery;
- •Symptomatic brain metastasis;
- •Uncontrolled systemic disease,such as infection,unstable diabetes mellitus,etc;
- •Active infection of HIV、HBV、HCV；
- •Major surgery within 4 weeks of start of study treatment, without complete recovery.
- •Pregnant or lactating women.Negative serum pregnancy test (For women of childbearing potential);Fertile patients must use effective contraception.
- •Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;
- •Received any investigational drug treatment within 4 weeks of start of study treatment.
研究组 & 干预措施
bevacizumab
Experimental
The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
干预措施: bevacizumab (Drug)
结局指标
主要结局
adverse events
时间窗: during the treatment in the hospital,an expected average of 1 week
participants will be followed for the duration of hospital stay, an expected average of 1 week
Maximum tolerated dose
时间窗: 1 week
during the treatment in the hosptital
次要结局
- Objective response rate(1 week)
- time to treatment failure(TTF)(1 month)
- time to death(TTD)(2 months)
研究者
Shen Lin
Director of GI oncology
Peking University
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion ChemotherapyOvarian Cancer With Malignant AscitesNCT01838538Chinese PLA General Hospital54
已完成
不适用
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant AscitesRefractory Malignant AscitesNCT02891369Fondation Hôpital Saint-Joseph30
招募中
2 期
A Clinical Trial With Apatinib for Subjects With Refractory Malignant AscitesMalignant AscitesApatinibNCT03020979The First Affiliated Hospital of Bengbu Medical University120
已完成
3 期
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.Colorectal CancerNCT01169558Hoffmann-La Roche168
Unknown
2 期
Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural EffusionMalignant Pleural EffusionNCT02054078Tang-Du Hospital183